Abstract: This invention encompasses compounds of the formula: ##STR1## where either R.sub.1 or R.sub.2 represents ##STR2## and the other represents hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms; andX is oxygen, methylene, or NH;Y is represents various inorganic and organic substituents;Z is hydrogen, amino or NHR.sub.6 where R.sub.6 is lowere alkyl having 1-6 carbon atoms;T is hydrogen, halogen, hydroxy, or lower alkoxy having 1-6 carbon atoms; andA is methylene, carbonyl or CHOH.These compounds are selective partial agonists or antagonists at brain monoamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neurolepticagents.

Abstract: The invention relates to a washing and/or conditioning composition for keratinous materials containing, in an aqueous medium suitable for these materials, at least one silicone containing a hydroxyacylamino functional group, at least one substantive polymer and at least one detergent surface-active agent.

Abstract: An etching solution comprising (A) an amine as a solvent, (B) an alkali metal compound, and (C) an alcohol as a solvent, this etching solution being a non-aqueous solution. This etching solution is-effective for etching a cured epoxy resin layer for forming holes for interstitial via holes having a small diameter, in the production of a multilayer printed circuit board. This etching solution is particularly effective for etching a cured epoxy resin layer formed from a thermosetting epoxy resin composition including (a) an epoxy resin, (b) a crosslinking agent, and (c) a polyfunctional epoxy resin, which forms a thermosetting copper-clad adhesive resin sheet which covers an interlayer circuit plate of a multilayer printed circuit board.

Abstract: A process for hydrogenating a compound in the group of the imines or enamines I to an amine II in the presence of a nitrile III, said nitrile III being essentially not hydrogenated comprises reacting a mixture comprising a compound I and a nitrile III with a gas comprising molecular hydrogen in the presence of a catalyst IV.

Abstract: Disclosed is a method for producing an acyl group-containing hexaazaisowurtzitane derivative represented by the following formula (1),WA.sub.n H.sub.(6-n) (1)wherein n represents an integer of 4 or 6, each A independently represents an acyl group having 1 to 10 carbon atoms, H represents a hydrogen atom, and W represents a hexavalent hexaazaisowurtzitane residue represented by the following formula (2): ##STR1## which comprises: providing a composition system comprising a mixed solvent of a first solvent and a second solvent respectively having high and low dissolving abilities for the desired compound, wherein the mixed solvent has the desired compound dissolved therein; and removing the first solvent having a high dissolving ability from the composition system to thereby deposit crystals of the desired compound. The desired compound, which is useful as a precursor of high performance explosive additive, i.e.

Abstract: Purified and crystallized riboflavin is prepared by a process that includes dissolving needle-shaped riboflavin of the stable modification A form in an aqueous mineral acid solution at a temperature not exceeding about 30.degree. C. with intensive intermixing. Active charcoal is then added to the resulting solution. After adsorption of the dissolved impurities from the solution onto the active charcoal, the solution containing the active charcoal is subjected to counter-current filtration over a ceramic membrane having a pore size of about 20 to about 200 nm. The resulting filtrate is treated with a five- to ten-fold amount of water (vol./vol.) at a temperature not exceeding about 30.degree. C. The resulting precipitated, spherical crystals of riboflavin are then separated by centrifugation or filtration. If desired, the spherical crystals of riboflavin may be washed with water and subsequently dried.

Abstract: Procedures for preparing compounds of formula (I) ##STR1## in which n, p and q or independently 0 or 1, are prepared according to the reaction scheme: ##STR2##

Abstract: Compounds of formulae (I) and (II) ##STR1## wherein the R, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 groups have the meanings defined in the disclosure, are useful chelants for metal ions. The complexes of compounds (I) and (II) with paramagnetic ions are useful as contrast agents for M.R.I. imaging.

Abstract: A process for preparing .chi.-form metal free phthalocyanine comprising: dry milling amorphous-like .alpha.-form metal free phthalocyanine to form .chi.-form metal free phthalocyanine partially; and wet milling or dispersing with stirring the resulting polymorph mixture in the presence of a cyclic organic solvent comprising an amide moiety. A simple process for preparing high-pure .chi.-form H2-Pc suitable as a charge generating meterial of an organic photoreceptor is provided, by improving the conventional technique for preparing .chi.-form H2-Pc.

Abstract: The invention relates to a compound of formula (I) ##STR1## Wherein: B is adenine, guanine or hypoxanthineZ is hydrogen or a negative chargeR is --[CH.sub.2 CH(R.sup.1)--O].sub.n -R.sup.2, --CH.sub.2 CH.sub.2 X, in whichR.sup.1 is hydrogen or (C.sub.1 -.sub.6) alkylR.sup.2 is hydrogen or (C.sub.1 -.sub.6) alkyln is a number from 1 to 6X is OH, F, NR.sup.3 R.sup.4R.sup.3 and R.sup.4 are independently from each other hydrogen or (C.sub.1 -.sub.6) alkyland to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.

Abstract: This invention relates to a process for the preparation of polyether-including chlorins and/or bacteriochlorins, comprising the following steps:(a) bonding a polyether to a porphyrin and(b) reacting the polyether-including porphyrin with a reducing agent.Furthermore, this invention concerns the polyether-including chlorins and bacteriochlorins, obtained by the process, as well as the use thereof for the photodynamic treatment of tumors.

Abstract: A compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinim, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Abstract: Method for recovering oxygen from a medium containing O.sub.2 using polynitrogenated compounds that have five coordinating functions which are capable of binding a metal atom, particularly a cobalt atom. In the recovery method, oxygen is first absorbed by the metal complex and then desorbed from the complex and recovered in an appropriate vessel.

Abstract: The present invention produces novel cis-oxazolidinone compound which is racemic form or optically active form, of a formula (1) ##STR1## wherein R represents C.sub.1 -C.sub.6 alkyl group, C.sub.2 -C.sub.6 alkenyl group, C.sub.1 -C.sub.6 alkoxyl group, C.sub.1 -C.sub.6 alkylamino group, aryl group or halogen atom, and oxazolidinone ring is at cis-configuration, comprising reacting cis-1,2-indene epoxide of a formula (3) ##STR2## form, with sulfonyl isocyanate compound of a formula (4) ##STR3## in the presence of metal halide catalyst. Further, cis-1-amino-2-indanol is produced by hydrolyzing the oxazolidinone compound. The latter compound is useful as an intermediate of HIV-drug.

Abstract: A process for the re-racemisation of a (-)-2-phenylmethyl-3,3-dimethyl-piperidin-4-on derivative wherein a (-)-2-phenylmethyl-3,3-dimethyl-piperidin-4-on derivative of the formula 8.sub.BwhereinR.sub.2 denotes hydrogen C.sub.1 -C.sub.6 -alkyl, halogen, C.sub.1 -C.sub.8 -alkoxy, a benzoyl group bound via an oxygen or an alkylcarboxyl group having a straight chained or branched C.sub.1 -C.sub.6 -lower alkyl group--wherein the alkyl group may optionally be substituted by one or more halogen atoms which may be identical or different;is heated to yield a racemic mixture of compounds of the formulae 8.sub.A and 8.sub.

Abstract: Described are novel reversible photochromic compounds of the homoazaadamantane spirooxazine family. Certain substituents are present on the nitrogen atom of the homoazaadamantane portion of the compound and on the benzene ring fused to the oxazine portion of the compound. These compounds may be represented by the following formula: Also described are compositions, e.g., solvent based mediums and polymerized organic materials, used to produce ophthalmic components, that contain the homoazaadamantane compounds with or without other photochromic compounds.

Abstract: 3-,8-substituted deuteroporphyrin derivatives with various substituents in the 13- and 17-positions of the porphyrin skeleton are suitable as pharmaceutical agents for use in photodynamic therapy (PDT) and for MRI therapy monitoring.

Abstract: This invention relates to novel inhibitors of androgen synthesis that are useful in the treatment of prostate cancer and benign prostatic hypertrophy. The present invention also provides methods of synthesizing these novel compounds, pharmaceutical compositions containing these novel compounds, and methods of treating prostate cancer and benign prostatic hypertrophy using the androgen synthesis inhibitors of the present invention.

Abstract: Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.

Abstract: The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is very efficient and robust macrocyclization methodology.